Trial reportSignal transduction and targeted therapy2025
First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II randomized study.
Trial report in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05218889 (Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer: a Prospective, Randomized Controlled Clinical Trial
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Advancing precision immunotherapy in advanced pancreatic cancer: a systematic review and meta-analysis of first-line ICI-based combinations.Frontiers in immunology · 2026Pooled it
- Review
- A Triple-Stage Precision Carbon Dot Nanogel With Cascade Activation for Spatiotemporally Controlled Chemo-Photodynamic Therapy.Advanced healthcare materials · 2026Article
- Efficacy of nab-paclitaxel combined with immune checkpoint inhibitors in solid tumors: a systematic review and meta-analysis of randomized controlled trials.Translational cancer research · 2026Article
- Safety and efficacy of the MNK/VEGFR inhibitor JDB153 combined with the anti-PD-1 antibody serplulimab in patients with advanced pancreatic cancer refractory to standard treatment: a single-arm, phase Ib/II study protocol.Frontiers in pharmacology · 2026Article
- Targeting the gut-pancreatic axis: microbial modulation of immunotherapy in pancreatic cancer.Frontiers in immunology · 2026Review
- A real-world retrospective analysis to evaluate the efficacy and safety of surufatinib in the treatment of advanced neuroendocrine neoplasms in China.Endocrine connections · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis and limited first-line treatments. This phase Ib/II randomized trial (NCT05218889) investigated the efficacy and safety of surufatinib plus camrelizumab and nab-paclitaxel/S-1 (NASCA) versus nab-paclitaxel and gemcitabine in patients with locally advanced or metastatic PDAC. The primary endpoints were dose-limiting toxicities and the recommended phase II dose (RP2D) of surufatinib in phase Ib, and the objective response rate (ORR) in phase II. Phase Ib used a 3 + 3 dose-escalation design to determine the RP2D of surufatinib in six patients, which was established at 200 mg. In phase II, patients were randomized 1:1 to receive the NASCA (45 patients) or nab-paclitaxel and gemcitabine (45 patients). NASCA group showed an ORR of 51.1% (23/45) versus 24.4% (11/45) in the nab-paclitaxel and gemcitabine group (odds ratio 3.2, 95% CI 1.3-8.2, p = 0.01). The median progression-free survival (PFS) was 7.9 vs. 5.3 months (HR 0.63, 95% CI 0.40-0.99, p = 0.045). The median overall survival was 13.0 vs. 11.0 months (HR 0.77, 95% CI 0.47-1.28, p = 0.318). The most common Grade ≥3 treatment-related adverse event was decreased neutrophil count (33.3% vs. 35.6%). In the NASCA group, enrichment of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.